ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Merck & Co. has entered an exclusive licensing agreement with Taiho Pharmaceutical and Astex Pharmaceuticals for small-molecule cancer drugs that inhibit KRAS. Merck will pay the companies $50 million up front and up to $2.5 billion more depending on drug development and sales milestones. KRAS, one of the frequently mutated genes in cancer, has proved a challenging target for drug development. Taiho and Astex are both part of Japan’s Otsuka Pharmaceutical.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X